Open Access

Levels of MUC1 in tumours and serum of patients with different sub‑types of squamous cell carcinoma of the head and neck

  • Authors:
    • Linda Boldrup
    • Philip Coates
    • Xiaolian Gu
    • Lixiao Wang
    • Robin Fåhraeus
    • Torben Wilms
    • Nicola Sgaramella
    • Jonathan Baumgarth
    • Lena Norberg‑Spaak
    • Karin Nylander
  • View Affiliations

  • Published online on: June 17, 2020     https://doi.org/10.3892/ol.2020.11746
  • Pages: 1709-1718
  • Copyright: © Boldrup et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mucin 1 (MUC1) is a membrane‑bound and secreted glycoprotein that has a protective role in surface epithelia. We recently demonstrated that MUC1 mRNA expression was upregulated in tumour‑free tongue tissues adjacent to squamous cell carcinoma of the oral tongue (SCCOT) compared with that in the tumour tissues. The present study investigated MUC1 protein in SCCOT tissue and serum from patients with squamous cell carcinoma of the head and neck (SCCHN) at different sub‑sites. The results from immunohistochemistry demonstrated that all SCCOT tissues expressed MUC1; however, the protein levels were not correlated with MUC1 mRNA levels in the same tumours. Furthermore, serum MUC1 level was lower in patients with SCCOT, tonsil SCC and gingival SCC compared with that in healthy subjects; however, the difference was only significant for patients with SCCOT (P=0.0421). No correlation was seen between MUC1 level in tumour tissues and MUCI level in serum from the same patients. The absence of correlation between MUC1 protein and mRNA levels in SCCOT tissues emphasized the importance of validating genomic data in clinical samples. Although significant MUC1 downregulation was observed in the serum of patients with SCCOT, there was a large variation within the groups, suggesting that MUC1 may not be used as a biomarker for these types of tumors.

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Boldrup L, Coates P, Gu X, Wang L, Fåhraeus R, Wilms T, Sgaramella N, Baumgarth J, Norberg‑Spaak L, Nylander K, Nylander K, et al: Levels of MUC1 in tumours and serum of patients with different sub‑types of squamous cell carcinoma of the head and neck. Oncol Lett 20: 1709-1718, 2020
APA
Boldrup, L., Coates, P., Gu, X., Wang, L., Fåhraeus, R., Wilms, T. ... Nylander, K. (2020). Levels of MUC1 in tumours and serum of patients with different sub‑types of squamous cell carcinoma of the head and neck. Oncology Letters, 20, 1709-1718. https://doi.org/10.3892/ol.2020.11746
MLA
Boldrup, L., Coates, P., Gu, X., Wang, L., Fåhraeus, R., Wilms, T., Sgaramella, N., Baumgarth, J., Norberg‑Spaak, L., Nylander, K."Levels of MUC1 in tumours and serum of patients with different sub‑types of squamous cell carcinoma of the head and neck". Oncology Letters 20.2 (2020): 1709-1718.
Chicago
Boldrup, L., Coates, P., Gu, X., Wang, L., Fåhraeus, R., Wilms, T., Sgaramella, N., Baumgarth, J., Norberg‑Spaak, L., Nylander, K."Levels of MUC1 in tumours and serum of patients with different sub‑types of squamous cell carcinoma of the head and neck". Oncology Letters 20, no. 2 (2020): 1709-1718. https://doi.org/10.3892/ol.2020.11746